Kyntra Bio, Inc.(KYNB)

$7.07—Stale · unknown old

Ask SA Chart

Kyntra Bio, Inc.(KYNB)

NASDAQ • Last print unknown ago

$7.07—Stale · unknown old

Ask SA Chart Studio

KYNB(KYNB)

KYNB

9/18/26

Kyntra Bio (KYNB)

Friday

11:21 AM

ThesisRecent clinical trial results and strategic partnerships have improved market sentiment around Kyntra Bio, positioning it favorably against competitors.

Revenue Outlook

Metric	FY2025	FY2026E	FY2027E
Revenue	$6M	$7M	$8M
Rev. Growth	-78.3%	+5.1%	+20.2%
EPS	$45.37	$-8.40	$-12.58
EPS Growth	+9552%	-119%	-49.7%
P/E	0.2×	—	—

★ Analysts see FY2027 revenue reaching $8M — +20.2% growth in a single year.

What’s Driving the Stock

01Kyntra Bio's lead product candidate has shown a 75% efficacy rate in Phase 2 trials, significantly above the industry average of 50%.
02The company secured a $50M partnership deal with a major pharmaceutical firm for its gene-editing technology.
03Recent patent approvals for its gene-editing technology extend exclusivity by an additional 5 years.
04A competitor's recent clinical trial failure has opened the market for Kyntra's therapies, potentially increasing market share.
05Precision medicine advancements
06Increased investment in biotech R&D
07FDA approval of clinical trials for its lead product candidate
08Partnership announcements with larger pharmaceutical companies

FY2025 Snapshot

Revenue: $6M
Rev. Growth: -78.3%
Gross Margin: 91.4%
Op. Margin: -713%
Net Margin: 2849%
Net Income: $183M
NI Growth: +486%
EPS: $45.37
1Y Return: -38.3%

KYNB Chart

My Notes

"Our recent advancements in gene-editing technology position us to lead in the treatment of rare diseases."
Moat: Kyntra Bio's proprietary technology and strong patent portfolio provide a significant barrier to entry for competitors.
growth - Investors looking for high-risk, high-reward opportunities in the biotech sector.
Higher interest rates can increase the cost of capital for Kyntra Bio, impacting its ability to finance R&D and clinical trials…
Watch on earnings: FDA approval timelines, Clinical trial success rates, Partnership revenue growth.

One Sentence Summary:

The bull case is simple: analysts see revenue climbing from $7M to $8M as kyntra bio's lead product candidate has shown a 75% efficacy rate in phase 2 trials.

Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance

Metric

FY2025

FY2026E

FY2027E

P/E

0.2×

—

What’s Driving the Stock

01Kyntra Bio's lead product candidate has shown a 75% efficacy rate in Phase 2 trials, significantly above the industry average of 50%.

02The company secured a $50M partnership deal with a major pharmaceutical firm for its gene-editing technology.

03Recent patent approvals for its gene-editing technology extend exclusivity by an additional 5 years.

04A competitor's recent clinical trial failure has opened the market for Kyntra's therapies, potentially increasing market share.

05Precision medicine advancements

06Increased investment in biotech R&D

07FDA approval of clinical trials for its lead product candidate

08Partnership announcements with larger pharmaceutical companies

My Notes

"Our recent advancements in gene-editing technology position us to lead in the treatment of rare diseases."

Moat: Kyntra Bio's proprietary technology and strong patent portfolio provide a significant barrier to entry for competitors.

growth - Investors looking for high-risk, high-reward opportunities in the biotech sector.

Higher interest rates can increase the cost of capital for Kyntra Bio, impacting its ability to finance R&D and clinical trials…

Watch on earnings: FDA approval timelines, Clinical trial success rates, Partnership revenue growth.